J
James D. Neaton
Researcher at University of Minnesota
Publications - 352
Citations - 68183
James D. Neaton is an academic researcher from University of Minnesota. The author has contributed to research in topics: Risk factor & Blood pressure. The author has an hindex of 101, co-authored 331 publications receiving 64719 citations. Previous affiliations of James D. Neaton include University of Pittsburgh & Medical Research Council.
Papers
More filters
Journal ArticleDOI
Regulatory impediments jeopardizing the conduct of clinical trials in Europe funded by the National Institutes of Health
James D. Neaton,Abdel Babiker,Mark Bohnhorst,Janet Darbyshire,Eileen Denning,Arnie Frishman,Jesper Grarup,Gregg Larson,Jens D Lundgren +8 more
TL;DR: Disharmony, at multiple levels, in international regulations and guidelines is stifling publicly funded global research and international scientific organizations and government groups should make the documentation and solution of these problems a priority.
Journal ArticleDOI
Analysis of an ordinal endpoint for use in evaluating treatments for severe influenza requiring hospitalization
Ross L. Peterson,David M. Vock,John H. Powers,Sean Emery,Eduardo Fernandez Cruz,Sally Hunsberger,Mamta K. Jain,Sarah Pett,Sarah Pett,James D. Neaton +9 more
TL;DR: Deviations from proportional odds reduced power at most from 80% to 77% given the same overall treatment effect as specified in the FLU-IVIG protocol.
Journal Article
Elevated Prostate-Specific Antigen Levels Up to 25 Years Prior to Death from Prostate Cancer
TL;DR: PSA levels measured from blood obtained before the introduction of widespread PSA testing were a strong predictor of prostate cancer death over 25 years of follow-up, with increased risk observed even at moderate levels of PSA.
Journal ArticleDOI
Which HIV-infected adults with high CD4 T-cell counts benefit most from immediate initiation of antiretroviral therapy? A post-hoc subgroup analysis of the START trial.
Jean-Michel Molina,Birgit Grund,Fred M. Gordin,Ian Williams,Mauro Schechter,M. H. Losso,Matthew Law,Ernest Ekong,Noluthando Mwelase,Athanasios Skoutelis,Martin Wiselka,Linos Vandekerckhove,Thomas Benfield,David Munroe,Jens D Lundgren,James D. Neaton +15 more
TL;DR: Asymptomatic, HIV-positive adults with CD4 counts higher than 500 cells per μL who are older, have a low CD4 to CD8 ratio, or a high plasma HIV RNA viral load benefit most from immediate initiation of ART and should be prioritised for treatment.
Journal ArticleDOI
Multiple-stage screening and mortality in the Multiple Risk Factor Intervention Trial.
TL;DR: Differences between observed and predicted six-year total mortality for trial participants were largely attributable to volunteers and exclusions, but there were additional differences for CHD mortality, which were likely due to downward secular trends.